Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
Public ClinicalTrials.gov record NCT02636036. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Multicenter, Open Label Study of Enadenotucirev Combined With PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
Study identification
- NCT ID
- NCT02636036
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Akamis Bio
- Industry
- Enrollment
- 51 participants
Conditions and interventions
Interventions
- enadenotucirev Biological
- nivolumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 24, 2016
- Primary completion
- Oct 7, 2021
- Completion
- Oct 7, 2021
- Last update posted
- Nov 8, 2021
2016 – 2021
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center, 1515 North Campbell Ave. | Tucson | Arizona | 85724 | — |
| City of Hope Comprehensive Cancer Center, 1500 E Duarte Str. | Duarte | California | 91010 | — |
| UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360 | Santa Monica | California | 90095 | — |
| Horizon Oncology Research, 1345 Unity Place, Suite 365 | Lafayette | Indiana | 47905 | — |
| Henry Ford Hospital, 2799 West Grand Blvd. | Detroit | Michigan | 48202 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232-6307 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02636036, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2021 · Synced Jun 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02636036 live on ClinicalTrials.gov.